Symrise achieves organic sales grow...

Symrise reported Q3 2025 results that underscore pricing discipline, portfolio resilience, and strong capital market backing – factors with direct relevance to pet industry stakeholders and investors tracking stability in nutrition supply chains.

Within its Taste, Nutrition & Health (TNH) segment, which includes Pet Food, Symrise delivered 1.2% organic growth, generating 750 € million in Q3 revenues. Pet Food sales remained at the prior-year level, reflecting price adjustments implemented earlier in 2025 rather than a contraction in underlying demand. The company stated that the category continues to perform ‘in line with the market,’ confirming stability in a climate where many suppliers are still balancing inflationary input costs, pricing elasticity, and volume recovery.

While top-line growth in pet nutrition was neutral year-on-year, the performance signals strategic pricing execution rather than category weakness – an important distinction for manufacturers seeking dependable ingredient partners in a market defined by margin sensitivity and long product development cycles. The result further emphasizes that, unlike some adjacent nutrition segments, pet food demand has held structurally resilient despite macroeconomic pressure.

For investors, Symrise strengthened its balance sheet through a highly successful 800 million € bond issuance (7-year maturity, 3.25% coupon), backed by new investment-grade ratings: BBB+ (S&P) and Baa1 (Moody’s), both with stable outlooks. The raise was multiple times oversubscribed, reinforcing confidence in Symrise’s long-term positioning.

The company updated its 2025 organic growth outlook to 2.3% – 3.3%, while reaffirming EBITDA margins of ~21.5% and Business Free Cash Flow of ~14% of sales – key indicators of margin resilience and cash generation capacity. Cost-saving measures under the ONE SYM Transformation are on track to reach €40 million in 2025, with 75% already realized.

Looking ahead, Symrise reiterated 2028 mid-term targets of 5–7% CAGR, EBITDA margins up to 23%, and cash flow above 14% of sales – milestones that underpin its strategic appeal as a long-term innovation and supply partner to the global pet nutrition market.

Back to homepage